Dysregulated B cell function and disease pathogenesis in systemic sclerosis.

Area of Science:

• Immunology
• Rheumatology
• Pathogenesis of Systemic Sclerosis

Background:

• Systemic sclerosis (SSc) is an immune-mediated disease causing excessive extracellular matrix deposition.
• B cells infiltrate affected tissues and produce autoantibodies, indicating a key role in SSc.
• B cell activity directly enhances fibroblast collagen synthesis and cytokine production.

Purpose of the Study:

• To elucidate the fundamental role of B cells in the pathogenesis of Systemic Sclerosis.
• To investigate B cell contributions to fibrosis and immune dysregulation in SSc.
• To explore the therapeutic potential of targeting B cells in SSc.

Main Methods:

• Analysis of B cell infiltration in lesional sites.
• Coculture experiments with B cells and fibroblasts.
• Assessment of cytokine production (IL-6, TGF-β) by SSc B cells.
• Flow cytometry to analyze B cell subsets and activation markers (e.g., CD19).
• Review of therapeutic responses to B cell depletion (e.g., rituximab).

Main Results:

• B cells directly stimulate fibroblasts to increase collagen and extracellular matrix synthesis.
• SSc B cells produce profibrotic cytokines like IL-6 and TGF-β, fueling a pro-fibrotic loop.
• Increased total B cell counts and altered distributions of naive, memory, transitional, and regulatory B cells observed in SSc patients.
• Differential expression of activation markers on SSc B cells impacts immune cell interactions.
• Some SSc patients show therapeutic benefits from B cell depletion therapy.

Conclusions:

• B cells are central players in Systemic Sclerosis pathogenesis, driving fibrosis and contributing to immune dysregulation.
• Targeting B cells, as demonstrated by rituximab therapy, offers a potential therapeutic strategy for SSc.
• Impaired B cell signaling in SSc may prevent immune tolerance, warranting further investigation.